Connect with us
Prague Gaming & TECH Summit 2025 (25-26 March)

Fintech PR

DOLCE&GABBANA UNVEILS NEW DETAILS AND GLAMOROUS DESIGNS FOR COMMON SPACES IN ITS FIRST REAL ESTATE PROJECT IN THE USA, DEVELOPED BY JDS DEVELOPMENT GROUP

Published

on

dolce&gabbana-unveils-new-details-and-glamorous-designs-for-common-spaces-in-its-first-real-estate-project-in-the-usa,-developed-by-jds-development-group

MIAMI, March 27, 2024 /PRNewswire/ — Dolce&Gabbana has unveiled new design and flexible-residence details at 888 Brickell, its first real estate project and condo hotel in the USA, in collaboration with developer JDS Development Group. Introducing a first-of-its kind design feat, Dolce&Gabbana’s Grand Residences seamlessly transition into multiple individual rooms and suites which can be utilized simultaneously by owners and hotel guests without compromising privacy and featuring private entries for each. Buyers of the residences will have the opportunity to rent their Dolce&Gabbana-designed homes via the hotel program when they’re not in private use. The condo hotel features 250 rooms and suites, six food and beverage outlets, and a signature restaurant on the ground floor, two bars in the expansive Grand Lobby, Pool Club restaurant & bar for day-to-night deckside dining, demo kitchen and private dining. Designed with signature Dolce&Gabbana flair, the common spaces convey the unwavering dedication to craftsmanship for the unprecedented hybrid condo hotel and its lifestyle-driven hospitality and elevated residential experience.

The grand residential lobby boasts black marble with a dramatic feature wall of book-matched burgundy marble, and three grand custom-designed Venetian hand-made chandeliers. The signature hues of Dolce&Gabbana— black, gold, and red—are expertly interwoven into the interior design, culminating in a luxurious and cohesive ambiance. Ascending to the first floor, a striking black marble staircase stands as a sculptural centerpiece, offering access to hotel check-in and exclusive lounge areas and private reception spaces for residents and guests alike. A dramatic bar lounge is set to be a lavish retreat for entertaining and relaxing, and features a harmonious blend of sumptuous textures, including black and white marbles, cast glass, velvet (including the iconic zebra in black-on-black pattern) and polished nickel. The Dolce&Gabbana design experience culminates in the event space: a double height area meticulously designed to the finest detail, is complete with plush seating, a stage, and DJ booth. Bronze palms, amber-colored venetian chandeliers, and rich browns and greys adorn the space, accented by the brand’s signature leopard print. The designs epitomise the fashion house’s commitment to sourcing, fatto a mano’ (handmade) and well-considered materials in a perfect meeting of Italianate and Miami glamour and grace, complimented by world-class hospitality.

Dolce&Gabbana has collaborated with M2Atelier studio to translate the ideas and concepts expressed by Domenico Dolce and Stefano Gabbana for the interior design of 888 Brickell. Thanks to a well-established partnership and a deep mutual knowledge acquired in over twenty years of collaboration, Marco Bonelli and his team are the architectural force behind the creative minds of the Designers.

Additional amenities include the residential and hotel Dolce&Gabbana 888 Pool Club, including a gelateria, bar, and restaurant, in a palette of rich green terrazzo and crisp green and white striped-lounge chairs. Wellbeing amenities include a double-height indoor padel court, fitness center, golf simulator and yoga & pilates studios. The recovery spa – set to be an oasis of serenity in this bustling city – will include a thoughtfully-curated menu of bespoke massages and facial therapies, IV therapy, juice bar, thermal circuit, and a barber shop. Exclusive resident amenities include a theater, lounge, billiard’s room, children’s playroom, workspace and meeting suites, and 44′ lap pool. Altogether, the amenity suite epitomizes the style and vibrancy of its Miami and Brickell neighborhood location.

Alfonso Dolce CEO at Dolce&Gabbana says: “After the launch of our Casa Collection in 2021, it was natural to follow with a hotel and residential strategy ensuring the very best of Italian hospitality. For us, the cultural vibrancy of Miami is the perfect backdrop for our world debut in the real estate sector with ‘fatto a mano’ (handmade) craftsmanship at its heart. The project will embody the very essence of the Dolce&Gabbana universe – a luxurious, timeless design experience.”

Michael Stern, Founder and CEO at JDS Development Group says: “The global real estate spotlight is shining on Miami and Brickell, in particular due to many prominent businesses relocating to the area. This extraordinary, branded condo hotel for Miami will ensure that the demand for world leading, design led spaces with unparalleled views can be fulfilled; we are extremely proud to launch the collaboration with Dolce&Gabbana in this iconic tower. The fashion house’s pursuit of quality and detail in design — together with their ability to create a beautiful world of authentic lifestyle filled with incredible hospitality — guarantees we are embarking on a successful, creative journey for our future visitors, guests, and residents alike.”

888 Brickell Dolce&Gabbana Condo Hotel

Unique to 888 Brickell Dolce&Gabbana, these first-of-their-kind homes are designed for flexibility. A Dolce&Gabbana residence in its grandest form – a gracious three bedroom – can be transformed into Hotel Rooms and a Hotel Suite, should owners wish when they are not in residence, allowing guests to take advantage of the 5-star amenities offered by 888 Brickell. The Grand Private Residence has a minimum of two ensuite bedrooms, plus a powder room, living graciously alongside a corner great room which extends to a generous loggia with outdoor kitchen. When the secondary bedrooms are transitioned into high-style Hotel Rooms, the principal bedroom and great room – together with its outdoor loggia – become an intimate private residence or Hotel Suite. With a separate entrance from the private foyer, the thoughtfully conceived Hotel Room is a world of its own in Dolce&Gabbana splendor, independent of the corner Suite. Both the five-star hotel market and high-end condominium rental market continue to achieve premium rates in Miami compared to the rest of the hotel and high-end rental market, respectively.

The Miami 5-star hotel average daily rate in 2023 was more than $1,000 per night, a 48% increase from 2019. Brickell two-bedroom condominiums rent for more than double the figures of two bedrooms in high-end Brickell rental buildings, signaling the demand for high end residential product in this area. And between 2020 and 2021, migration into Miami from New York, Los Angeles, and Chicago brought $3.7 billion in taxable income. Growth in income of renters in Southeast Florida has increased 28% since 2019, largely because 58% of the jobs added in Florida since 2020 are in professional and business services, finance, and information technology.

The Tower

Advertisement

A striking new addition to the Magic City skyline, 888 Brickell, Dolce&Gabbana, Miami will be the tallest building in the city at 1,049 feet (319.74 meters), establishing a new standard in the architectural landscape. The façade is to be designed in collaboration with architects Studio Sofield, inspired by both quintessential modernist skyscrapers and Milanese mid-century design and fashion. The elegant and restrained combination of ivory travertine and matt black steel beams that give the building an expressly vertical appearance, setting it far apart from its neighbors. Towards street level, the building dons a gold beaded ‘necklace’ that brings a warm lustre and brilliant shine.

Website: www.888.dolcegabbana.com 

Residential sales are managed by OFFICIAL www.officialpartners.com 

Link to high res images: https://www.dropbox.com/scl/fo/0qkzah2278u08qu9zztum/h?rlkey=7eij3m00zba497dl73llq2bz4&dl=0

ABOUT DOLCE&GABBANA Established in 1984, Dolce&Gabbana is an international leader in the fashion and luxury goods sector. The founders, Domenico Dolce and Stefano Gabbana, have always been the creative and stylistic source of all the brand’s activities as well as the drivers behind the development strategies. The Group creates, produces and distributes high-end clothing, leather goods, footwear, accessories, jewellery and watches. The brand is present in the prêt-à-porter segment with Men’s, Women’s and Children’s Collections. Since 2012, the brand has developed the Alta Moda project which further expanded into Alta Sartoria, Alta Gioielleria and Alta Orologeria Collections. In 2021, Dolce&Gabbana launched Dolce&Gabbana Casa, a homeware line dedicated to furniture and furnishing complements.

ABOUT JDS DEVELOPMENT GROUP Known for best-in-class engineering and record-breaking architecture the world over, JDS Development Group brings their breadth of experience to Miami, where it is headquartered. Composed of a team of innovators and builders led by Michael Stern, JDS is no stranger to large scale urban development and constantly pushes the boundaries of engineering and design, disrupting the skyline as often as they break ground.

Photo – https://mma.prnewswire.com/media/2373287/JDS_Development_Dolce_Gabbana.jpg
Photo – https://mma.prnewswire.com/media/2373290/JDS_Development_Dolce_Gabbana.jpg
Photo – https://mma.prnewswire.com/media/2373291/JDS_Development_Dolce_Gabbana.jpg
Photo – https://mma.prnewswire.com/media/2373292/JDS_Development_Dolce_Gabbana.jpg

 

The Lounge Bar at 888 Brickell by Dolce&Gabbana and JDS Development Group

 

The Lounge at 888 Brickell by Dolce&Gabbana and JDS Development Group

 

888 Brickell by Dolce&Gabbana and JDS Development Group

 

Cision View original content:https://www.prnewswire.co.uk/news-releases/dolcegabbana-unveils-new-details-and-glamorous-designs-for-common-spaces-in-its-first-real-estate-project-in-the-usa-developed-by-jds-development-group-302101410.html

Continue Reading
Advertisement
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Fintech PR

Fixed income investor meetings – update

Published

on

fixed-income-investor-meetings-–-update

FORNEBU, Norway, Jan. 15, 2025 /PRNewswire/ — Reference is made to the announcement by Aker Horizons ASA (“Aker Horizons” or the “Company”) on 9 January 2025 regarding fixed income investor meetings and a potential new bond issue. The Company has met a broad range of investors and experienced strong interest from the market.

The Company has received valuable feedback, which it will evaluate as part of the ongoing process to optimize the Company’s overall capital structure. Accordingly, the Company will not pursue a potential bond offering at this time. 

Aker Horizons has a robust liquidity position and benefits from strong support from its main shareholder and creditor Aker ASA. The Company is committed to its strategy of developing green energy and green industry. 

For further information, please contact:
Stian Andreassen, Investor Relations, Tel: +47 41 64 31 07
[email protected]

Mats Ektvedt, Media, Tel: +47 41 42 33 28
[email protected]

About Aker Horizons:

Aker Horizons develops green energy and green industry to accelerate the transition to Net Zero. The company is active in renewable energy, carbon capture and sustainable industrial assets. As part of the Aker group, Aker Horizons applies industrial, technological and capital markets expertise with a planet-positive purpose to drive decarbonization globally. Aker Horizons is listed on the Oslo Stock Exchange and headquartered in Fornebu, Norway. Across its portfolio, the company is present on five continents. www.akerhorizons.com

This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.

IMPORTANT INFORMATION

This communication is not an offer to sell or purchase, or the solicitation of an offer to sell or purchase, any securities, or the solicitation of a proxy, in any jurisdiction in which, or to any person to whom, such offer, sale or solicitation is not authorized or would be unlawful.

Advertisement

This communication contains forward-looking statements. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events or performance, and other statements, which are not statements of historical facts. Forward-looking statements are generally identified by the words “expects”, “anticipates”, “believes”, “intends”, “estimates”, “plans”, “will be” and similar expressions. You are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of the Company, and that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward -looking information and statements contained herein. The forward-looking statements in this communication speak only as of the date hereof and, other than as may be required by applicable law, the Company does not undertake any obligation to update or revise any forward-looking information or statements.

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/aker-horizons/r/fixed-income-investor-meetings—update,c4091958

View original content:https://www.prnewswire.co.uk/news-releases/fixed-income-investor-meetings—update-302352166.html

Continue Reading

Fintech PR

Statement of Ad Hoc Lebanon Bondholder Group

Published

on

statement-of-ad-hoc-lebanon-bondholder-group

LONDON and NEW YORK, Jan. 15, 2025 /PRNewswire/ — In March 2020, several of the largest institutional holders of sovereign bonds issued by Lebanon formed a group (the “Ad Hoc Group”) in response to the deteriorating financial and economic situation in the country and the government’s decision to default on its international bonds.  The Ad Hoc Group’s stated objective from the outset has been to find a sustainable and equitable solution to Lebanon’s severe debt challenges. The Ad Hoc Group is supported by White & Case LLP as legal advisor. 

The intervening years have witnessed a further decline of Lebanon’s political, economic and security situation, which has prevented any meaningful engagement with the Lebanese authorities.  Despite the lack of progress to date, the Ad Hoc Group continues to provide a forum for coordination and communication among international bondholders, and remains prepared to engage constructively with the Lebanese authorities and other domestic and international stakeholders.

In this regard, the Ad Hoc Group is encouraged by the recent election of Joseph Aoun as President of Lebanon and nomination of Nawaf Salam as prime minister, and looks forward to the formation of a new government that will have the mandate to address the many challenges facing the country. 

The Ad Hoc Group also takes note of last week’s statement of the Council of Ministers of Lebanon relating to the proposed suspension of Eurobond prescription periods until 9 March 2028, and confirms its willingness to discuss the implementation of the proposed suspension with the authorities and, at the appropriate time, to engage more broadly to find a resolution to the longstanding debt default.

Holders of Lebanon’s international bonds who wish to learn more about the Ad Hoc Group and its objectives, or discuss recent developments, may contact White & Case LLP by emailing [email protected].

View original content:https://www.prnewswire.co.uk/news-releases/statement-of-ad-hoc-lebanon-bondholder-group-302351961.html

Continue Reading

Fintech PR

Cutting-Edge Cancer Therapies Lead the Way into a Transformative Year

Published

on

cutting-edge-cancer-therapies-lead-the-way-into-a-transformative-year

Issued on behalf of Oncolytics Biotech Inc.

USA News Group News Commentary

VANCOUVER, BC, Jan. 15, 2025 /PRNewswire/ — As 2025 begins, the American Association for Cancer Research (AACR) recently published forecasts from experts showcasing transformative advances in cancer research, including cutting-edge AI technologies, novel targeted therapies, and innovative cancer vaccines. With over 50 oncology drug approvals in 2024, including the first tumor-infiltrating lymphocyte cell therapy, this year holds great promise for precision medicine and immunotherapy. Amid growing expectations for an active year for biotech stocks in 2025, developers of new cancer therapies are already releasing important developments, with recent news coming from Oncolytics Biotech Inc. (NASDAQ: ONCY) (TSX: ONC), Adaptive Biotechnologies Corporation (NASDAQ: ADPT), NeoGenomics, Inc. (NASDAQ: NEO), Elevation Oncology, Inc. (NASDAQ: ELEV), and ORIC Pharmaceuticals, Inc. (NASDAQ: ORIC).

The article continued: Statista analysts project that the oncology drugs market will generate an estimated revenue of $208.9 billion in 2025. Meanwhile, Global Market Insights reports that the global oncology market, valued at approximately $320.3 billion in 2024, is expected to grow at a compound annual growth rate (CAGR) of 10.8% from 2025 to 2034, reaching $866.1 billion.

Regulatory Approval Clears Path for Oncolytics Biotech® to Advance Promising Pancreatic Cancer Treatment, Following a Review of Safety Data

Oncolytics Biotech Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for oncology, today announced that Germany’s medical regulatory body, the Paul-Ehrlich-Institute (PEI), has approved the continuation of patient enrollment into Cohort 5 of the GOBLET study. This cohort is evaluating pelareorep in combination with modified FOLFIRINOX (mFOLFIRINOX) with or without atezolizumab (Tecentriq®) in newly diagnosed pancreatic ductal adenocarcinoma (PDAC) patients.

Following a positive safety review by the independent Data Safety Monitoring Board (DSMB), which recommended continuation, the PEI’s approval allows Cohort 5 to progress to full enrollment. Early safety data will be presented at the upcoming 2025 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium later this month, with initial efficacy results expected in the second half of the year.

“Pelareorep has the potential to meaningfully improve outcomes for patients with metastatic pancreatic cancer,” said Thomas Heineman, M.D., Ph.D., Chief Medical Officer for Oncolytics Biotech. “Encouraging tumor response rates observed in an earlier cohort of the GOBLET study underscore pelareorep’s promise in this disease. GOBLET Cohort 5 extends our evaluation by testing pelareorep with a different chemotherapy regimen, mFOLFIRINOX, which broadens the range of pancreatic cancer patients who may benefit from this innovative therapy. Positive results from this cohort may ultimately enable pelareorep to benefit the large majority of metastatic pancreatic patients for whom improved treatment options are badly needed.”

The Phase 1/2 GOBLET study is testing pelareorep, an oncolytic reovirus, in combination with other treatments for advanced gastrointestinal cancers, including pancreatic, colorectal, and anal cancers. Conducted at 17 centers in Germany, the study aims to evaluate response rates, safety, and biomarkers across multiple treatment arms, with promising cohorts advancing to further testing.

AIO is a non-profit organization that evolved from the medical oncology working group within the German Cancer Society (DKG). Dedicated to advancing science and research in medical oncology, AIO has grown into a prominent sponsor and study management company. Over the years, it has established a strong reputation both within Germany and on the international stage for its contributions to oncology research and study development.

Advertisement

Oncolytics Biotech’s work represents a significant step forward in the fight against metastatic pancreatic cancer, addressing a critical need for more effective treatment options in this aggressive disease. By leveraging the innovative potential of pelareorep in combination with established therapies, the company is paving the way for breakthroughs that could transform outcomes for patients and unlock value for investors.

CONTINUED… Read this and more news for Oncolytics Biotech at:  https://usanewsgroup.com/2023/10/02/the-most-undervalued-oncolytics-company-on-the-nasdaq/ 

In other recent industry developments and happenings in the market include:

Adaptive Biotechnologies Corporation (NASDAQ: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, NeoGenomics, Inc. (NASDAQ: NEO), a leading oncology testing services company, recently announced a multi-year exclusive strategic commercial collaboration that will advance minimal residual disease (MRD) monitoring options for patients with select blood cancers.

Adaptive’s clonoSEQ® is the first and only FDA-cleared test for detecting minimal residual disease (MRD) in lymphoid cancers, while NeoGenomics’ COMPASS® and CHART® offer comprehensive and personalized testing for complex blood cancers. By combining clonoSEQ with these advanced services, oncologists can develop tailored treatment plans, assess patient risk more accurately, and gain real-time insights into disease progression, enhancing care for blood cancer patients.

“As a leader in oncology testing with an extensive menu of precision oncology offerings, NeoGenomics is a natural partner for us,” said Chad Robins, CEO and Co-Founder of Adaptive Biotechnologies. “We are proud of this collaboration, which expands access to the valuable insights that clonoSEQ MRD results offer, ultimately helping more providers and patients benefit from knowing their MRD status.”

Under a new agreement, clinicians using NeoGenomics’ COMPASS diagnostic tool for blood cancers like multiple myeloma, B-ALL, CLL, and DLBCL can now include Adaptive Biotechnologies‘ clonoSEQ Clonality (ID) test at diagnosis to identify patient-specific DNA sequences for ongoing MRD (minimal residual disease) tracking. This integration allows seamless monitoring of disease burden throughout treatment using CHART, giving patients access to clonoSEQ insights and increasing eligibility for clinical trials that rely on MRD testing to guide therapy decisions. All clonoSEQ testing will be conducted at Adaptive’s specialized laboratory, ensuring accurate and consistent results. 

Adaptive and NeoGenomics are preparing to implement the infrastructure for their partnership, with cross-promotional efforts expected to launch later this year, though financial terms remain undisclosed.

iBio, Inc. (NYSE-American: IBIO) an AI-driven innovator of precision antibody immunotherapies, in collaboration with AstralBio Inc., recently announced they’ve developed a breakthrough antibody targeting Activin E, a key protein linked to cardiometabolic disorders and obesity. This achievement demonstrates the strength of iBio’s platform in tackling challenging targets and advancing innovative therapies, with plans for rapid testing of this and other candidates in advanced disease models.

“Developing a functional antibody against Activin E, an achievement we believe to be an industry first, is a significant milestone for iBio,” said Martin Brenner, Ph.D., DVM, iCEO and Chief Scientific Officer of iBio. “This breakthrough strengthens our efforts to expand our therapeutics pipeline for the treatment of cardiometabolic disorders and obesity with innovative next-generation solutions.”

Advertisement

Elevation Oncology, Inc. (NASDAQ: ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs, recently announced program updates and upcoming milestones.

The company is advancing its pipeline with EO-3021, a potentially best-in-class antibody drug conjugate targeting Claudin 18.2 in advanced gastric/GEJ cancer, showing promising early results with a 42.8% overall response rate and a differentiated safety profile. The ongoing Phase 1 trial includes monotherapy and combination studies, with additional data expected in 2025 and 2026, while EO-1022, a HER3-targeting ADC for solid tumors, is progressing toward preclinical data release in 2025 and an IND filing in 2026.

“We are rapidly advancing EO-3021 to address significant unmet needs in treating earlier lines of advanced gastric/GEJ cancer, where we believe we have a unique ability to improve on the standard of care,” said Joseph Ferra, President and CEO of Elevation Oncology. “As we enter 2025, we are honing our focus, leveraging the competitive anti-tumor activity and differentiated safety profile of EO-3021 to explore combination approaches in the first- and second-line settings.”

ORIC Pharmaceuticals, Inc. (NASDAQ: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, recently provided early Phase 1b combination data for ORIC-944, operational highlights for 2024, and anticipated upcoming milestones.

ORIC-944, a potent PRC2 inhibitor, has shown strong potential in treating metastatic castration-resistant prostate cancer (mCRPC), with deep and durable PSA responses and a favorable safety profile in early Phase 1b combination trials with apalutamide and darolutamide. Alongside advancements in ORIC-114 for NSCLC, ORIC’s 2024 milestones include promising clinical data, strategic collaborations with Johnson & Johnson and Bayer, and a robust cash position expected to support operations into late 2026, positioning the company for continued progress in oncology drug development.

“We made strong progress on multiple fronts in 2024, most notably with the initiation of multiple cohorts for ORIC-114 in NSCLC and ORIC-944 in mCRPC,” said Jacob M. Chacko, M.D., President and CEO of Oric. “We also forged three strategic collaborations with leading pharma partners, strengthened our leadership team to expand functional capabilities, and completed a $125 million PIPE financing, extending our cash runway into late 2026. These accomplishments position us well for 2025 and beyond, with seven anticipated data readouts over the next 18 months as we advance toward potentially initiating registrational studies for ORIC-114 in the second half of 2025 and for ORIC-944 in early 2026.”

Source: https://usanewsgroup.com/2024/09/21/is-oncolytics-biotech-the-markets-most-undervalued-cancer-opportunity/ 

CONTACT:
USA NEWS GROUP
[email protected]
(604) 265-2873

DISCLAIMER: Nothing in this publication should be considered as personalized financial advice. We are not licensed under securities laws to address your particular financial situation. No communication by our employees to you should be deemed as personalized financial advice. Please consult a licensed financial advisor before making any investment decision. This is a paid advertisement and is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. USA News Group is a wholly-owned subsidiary of Market IQ Media Group, Inc. (“MIQ”). MIQ has been paid a fee for Oncolytics Biotech Inc. advertising and digital media from the company directly. There may be 3rd parties who may have shares of Oncolytics Biotech Inc., and may liquidate their shares which could have a negative effect on the price of the stock. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. Because of this conflict, individuals are strongly encouraged to not use this publication as the basis for any investment decision. The owner/operator of MIQ own shares of Oncolytics Biotech Inc. which were purchased in the open market, and reserve the right to buy and sell, and will buy and sell shares of Oncolytics Biotech Inc. at any time without any further notice commencing immediately and ongoing. We also expect further compensation as an ongoing digital media effort to increase visibility for the company, no further notice will be given, but let this disclaimer serve as notice that all material, including this article, which is disseminated by MIQ has been approved by Oncolytics Biotech Inc.; this is a paid advertisement, we currently own shares of Oncolytics Biotech Inc. and will buy and sell shares of the company in the open market, or through private placements, and/or other investment vehicles.

While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between the any predictions and actual results. Always consult a licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.

Advertisement

View original content:https://www.prnewswire.co.uk/news-releases/cutting-edge-cancer-therapies-lead-the-way-into-a-transformative-year-302351959.html

Continue Reading

Trending